Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

539 results
Display

Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?

Chun HS, Lee M

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Lee SW, Choi J, Kim SU, Lim YS

Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK, The Korean Association for the Study of the Liver (KASL)

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatocellular carcinoma statistics in South Korea

Chon YE, Jeong SW, Jun DW

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
An analysis of polygenic risk scores for non-alcoholic fatty liver disease

Jun DW

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The major diagnostic role of autoantibodies in the diagnosis of autoimmune hepatitis, a disease of all ages

Beenet L

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B

Liang LY, Lee HW, Wong VWS, Yip TCF, Tse YK, Hui VWK, Lui GCY, Chan HLY, Wong GLH

Background/Aims: Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort

Ting YW, Kong ASY, Zain SM, Chan WK, Tan HL, Mohamed Z, Pung YF, Mohamed R

Background/Aims: 17β-hydroxysteroid dehydrogenase 13 (HSD17B13) variants were recently reported to have significantly lower odds of non-alcoholic fatty liver disease (NAFLD). This is a two-part study that aimed to evaluate the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients

Wong YJ, Thurairajah PH, Kumar R, Fock KM, Law NM, Chong SY, Manejero FG, Ang TL, Teo EK, Tan J

Background/Aims: Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome

Lee HA, Lim J, Joo HJ, Lee YS, Jung YK, Kim JH, An H, Yim HJ, Jeen YT, Yeon JE, Lim DS, Byun KS, Seo YS

Background/Aims: Useful biomarkers for metabolic syndrome have been insufficient. We investigated the performance of serum milk fat globule-EGF factor-8 (MFG-E8), the key mediator of inflammatory pathway, in diagnosis of metabolic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry

Kim JM, Kim DG, Kim J, Lee K, Lee KW, Ryu JH, Kim BW, Choi DL, You YK, Kim DS, Nah YW, Kang KJ, Cho JY, Hong G, Yu HC, Moon JI, Choi D, Hwang S, Kim MS

Background/Aims: To analyze the incidence and risk factors of outcomes after liver transplantation (LT) in the Korean population. Methods: This study analyzed data from the liver cohort of Korean Organ Transplantation...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Changes in the epidemiology and management of bacterial infections in cirrhosis

Piano S, Tonon M, Angeli P

Patients with cirrhosis are susceptible to develop infections because of immune dysfunction, changes in microbiome and increase in bacterial translocation from the gut to systemic circulation. Bacterial infections can worse...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
β-blockers in advanced cirrhosis: More friend than enemy

Yoon KT, Liu H, Lee SS

Nonselective beta-adrenergic blocker (NSBB) therapy for the prevention of initial and recurrent gastrointestinal bleeding in cirrhotic patients with gastroesophageal varices has been used for the past four decades. NSBB therapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Anti-fibrotic treatments for chronic liver diseases: The present and the future

Odagiri N, Matsubara T, Sato-Matsubara M, Fujii H, Enomoto M, Kawada N

Liver fibrosis reflects tissue scarring in the liver due to the accumulation of excessive extracellular matrix in response to chronically persistent liver injury. Hepatocyte cell death can trigger capillarization of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical and serological prognostic markers in primary biliary cholangitis

Wilhelmi M

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

Kang SH, Cho Y, Jeong SW, Kim SU, Lee JW, On behalf of Korean NAFLD Study Group

There is some dissatisfaction with the term “nonalcoholic fatty liver disease (NAFLD),” which overemphasizes alcohol and underemphasizes the importance of metabolic risk factors in this disease. Recently, a consensus recommended...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Another oral antiviral treatment, but still far away from hepatitis B virus cure

Tseng TC

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Biopsy or cytology for diagnosing hepatic focal lesions?

Kim H

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact

Yip TCF, Wong GLH, Wong VWS

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A need for patient-centered care in managing patients with liver cirrhosis

Yoon EL

CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr